Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County. The planned Virginia facility is the first, and part of the company's $50 billion in US capital expansion commitments since 2020. At this site, Lilly will also boost its domestic manufacturing of antibody-drug conjugates (ADCs). To maximize the latest technology, digital integrations and automation, the company plans to engage locally, partnering with local universities and supporting community educational initiatives. The company plans to announce the three remaining US manufacturing sites this year and expects to begin making medicines at these four facilities within five years.